Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
about
Current status of co-occurring mood and substance use disorders: a new therapeutic targetA review of a national training initiative to increase provider use of MAT to address the opioid epidemic.Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizationsExtended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communitiesImpact of research network participation on the adoption of buprenorphine for substance abuse treatment.Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participantsAdopting evidence-based medically assisted treatments in substance abuse treatment organizations: roles of leadership socialization and funding streamsThe prescription of addiction medications after implementation of chronic care management for substance dependence in primary careAdoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programsBarriers to use of pharmacotherapy for addiction disorders and how to overcome them.Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.Supply of buprenorphine waivered physicians: the influence of state policies.Program Capacity to Eliminate Outcome Disparities in Addiction Health Services.Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel ProcessLeadership and Licensure for Drug Treatment and the Implementation of Co-Occurring Disorder Treatment in Community Mental Health CentersCorrelates of improvement in substance abuse among dually diagnosed veterans with post-traumatic stress disorder in specialized intensive VA treatmentAccess to Addiction Pharmacotherapy in Private Health Plans.A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.Improving Coordination of Addiction Health Services Organizations with Mental Health and Public Health Services.Financial factors and the implementation of medications for treating opioid use disorders.The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal StudyGrowth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.Rural substance use treatment centers in the United States: an assessment of treatment quality by locationUse of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities.Identifying and ranking implicit leadership strategies to promote evidence-based practice implementation in addiction health servicesCORRELATES OF INTERORGANIZATIONAL SERVICE COORDINATION IN COMMUNITY CORRECTIONSTreatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatmentVariation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.I heard about it from a friend: assessing interest in buprenorphine treatment.Barriers to primary care physicians prescribing buprenorphine.Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.Insurance Receipt and Readiness for Opportunities under the Affordable Care Act: A National Survey of Treatment Providers for Substance Use Disorders.Buprenorphine Treatment and Patient Use of Health Services after the Affordable Care Act in an Integrated Health Care System.Integration of Care in the Implementation of the Affordable Care Act: Changes in Treatment Services in a National Sample of Centers Treating Substance Use Disorders.
P2860
Q27014938-59AC21B7-7ADB-4CCC-8783-6E6D561FAFCBQ30239840-A5F5C9FB-2886-4058-95B5-80272C92BEE8Q30373948-74FC385E-798B-44C3-A978-F9276E63B352Q33595868-7763046E-27CC-4B2F-826A-1A801831581BQ33707278-4EF31343-F1BB-42FC-B3E0-6063A8D0B3EEQ33776944-44BB1899-D46F-498D-BAE1-90A05E879865Q34306652-3CB6DFFE-942D-4245-A8EA-06911B7A8834Q34602727-58102833-5075-4CAB-87F7-E2348A40EA4CQ34806644-4210FE03-F6AF-43C0-83B8-A9026DA5FD62Q35243514-C94883D2-8E64-4981-B495-5D6498D519FAQ35447234-45C3B3DD-1610-4382-8044-E766B4D56F4AQ35490468-FB269D58-FEDD-4A34-BF51-673C785D3D65Q35540686-8F9AACDF-F6BD-4474-9E46-977A0E5C87FAQ35571613-D2F7F9E6-9087-4D0B-AF1D-F6880E1717D1Q35674971-DAE78C88-2AF5-4C91-ABB9-CD7DCE3A39FFQ35752218-69F5529B-06D3-450B-8B8C-65605305CEBEQ35768063-A4F812F9-9D07-475F-9D2A-E084EF10BBBDQ35804723-CD5AA025-0FA6-4E9F-9828-337F18376503Q36025907-A6B572B8-4EE1-48FA-993A-727B1AC1DCE8Q36279198-0BF83552-C7AB-4268-970B-60FFA715DC39Q36328320-A2E43633-4361-477E-9506-759249ABF746Q36373003-650C4D33-D054-4806-9E9E-69E5354D8381Q36381418-B3407CCA-B038-45AB-9B5A-05397967CE52Q36494890-11F7AAA0-FC21-4568-96C9-304A7FE5AA85Q36549928-D89AD7C6-39D5-4939-958D-D8359F839DE3Q36597560-1A4FAFDA-D512-4874-AF6A-7B3E92592572Q36619638-4C8D48CD-18DF-4BFD-9E65-D57CCAA2FD9DQ36643013-B469DBEF-20A3-41E6-8437-F850FF0355FBQ36757250-DB7870CB-A3F8-4F25-B368-EB1FEB66B8DDQ36972481-DB6C4ED6-48C0-4AA9-88ED-3166DEE95EF9Q37183872-3E5E07A9-BE59-430E-83B7-3DEE6CFDEC1AQ37272343-6ABEEF33-D95A-4C1D-970D-9804ED98099BQ37281750-0B644761-586F-46CB-A17E-B53925001F6AQ37617894-0A3CC483-6B11-48B4-98C4-E056F5F64C9CQ37628725-8CE2D794-89DD-4EE8-BC3F-DC5C27EABAC3Q37729024-77C26F78-8847-4310-835A-B8081393A752Q37729027-074874BE-CDE9-47E7-9679-6CB8B4FAC762Q38730852-02F39036-E4C0-45A1-AC63-42B3ABB5A7ACQ38828787-12FCD0A8-99A9-41C0-A9DE-4578C061E07DQ38871371-6B934ACC-FDB8-4ED9-8F3C-12E8C0CA7D45
P2860
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Using medication-assisted trea ...... acilitators of implementation.
@ast
Using medication-assisted trea ...... acilitators of implementation.
@en
Using medication-assisted trea ...... acilitators of implementation.
@nl
type
label
Using medication-assisted trea ...... acilitators of implementation.
@ast
Using medication-assisted trea ...... acilitators of implementation.
@en
Using medication-assisted trea ...... acilitators of implementation.
@nl
prefLabel
Using medication-assisted trea ...... acilitators of implementation.
@ast
Using medication-assisted trea ...... acilitators of implementation.
@en
Using medication-assisted trea ...... acilitators of implementation.
@nl
P2093
P2860
P1433
P1476
Using medication-assisted trea ...... acilitators of implementation.
@en
P2093
Amanda J Abraham
Hannah K Knudsen
Paul M Roman
P2860
P304
P356
10.1016/J.ADDBEH.2011.01.032
P577
2011-01-27T00:00:00Z